Risk of suicidal behaviour is similar for SSRIs and tricyclics

doi:10.1136/bmj.329.7459.192-g

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ research articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Scott Gottlieb

New York

Risk of suicidal behaviour after starting to take antidepressants was similar for four antidepressant drugs, including selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants, a study in JAMA has found (2004;292:338-43). Suicidal behaviour is more likely in the first month after starting antidepressants, especially during the first nine days.

The researchers—Dr Hershel Jick and colleagues with the Boston Collaborative Drug Surveillance Program, Boston University, Massachusetts—compared the risk of non-fatal suicidal behaviour in patients in the United Kingdom who began treatment with one of three antidepressants (the SSRIs fluoxetine and paroxetine and the tricyclic amitriptyline) …